Login to Your Account



Darusentan Decent, But Can Cardio Fix Gilead's Patent Cliff?

By Trista Morrison


Monday, April 13, 2009
Gilead Sciences Inc.'s push to diversify away from HIV and into cardiovascular disease kicked into high gear with the proposed $1.4 billion acquisition of CV Therapeutics Inc. and positive data from a Phase III trial of Gilead's own resistant hypertension drug, darusentan.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription